

## CURRICULUM VITAE

Jack Thomas Stapleton, M.D.

### Personal Data

Citizenship Status: --b(6)--  
Social Security Number: ----b(6)-----  
Married: ---b(6)-----  
Children: ----b(6)-----

Address: Dept. of Internal Medicine  
SW54, GH UIHC  
200 Hawkins Drive  
Iowa City, IA 52242  
319-356-3168 (phone)

### Education

--b(6)---	(Biology)	Drake University, Des Moines, Iowa
--b(6)---	A.B.	University of Iowa, Iowa City, Iowa
1977-1980	M.D.	University of Kansas Kansas City, Kansas
1980-1983	Resident	Internal Medicine University of N Carolina, Chapel Hill, NC
1983-1984	Fellow	Microbiology University of N Carolina, Chapel Hill, NC
1984-1986	Fellow and Clinical Instructor	Infectious Diseases University of N Carolina, Chapel Hill, NC

### Academic Appointment

1986-1987	Instructor	University of Iowa
1987-1991	Assistant Professor	University of Iowa
1987-present	Staff Physician	Iowa City VA Medical Center
1988-1992	Research Associate	Veterans Administration
1988-present	Director, Virology (HIV/AIDS) Clinic	University of Iowa Hospitals and Clinics
1991-1996	Associate Professor (tenure)	University of Iowa
1996-present	Professor	University of Iowa
1999-2000	Advanced Career Enhancement Award	Veterans Admin.
1999-present	Director, Helen C. Levitt Center for Viral Pathogenesis and Disease	University of Iowa
2004-present	Faculty, Interdisciplinary Program in Molecular Biology	University of Iowa
2004 – present	Director, Division of Infectious Diseases	University of Iowa

### Certification

American Board of Internal Medicine	1983	--b(6)----
ABIM, Infectious Diseases Subspecialty Boards	1986	----b(6)----

### Licensure

North Carolina	--b(6)----
Iowa	--b(6)----

### Professional Affiliations

---b(6)\_, American College of Physicians (Fellow), American Association for the Advancement of Science, American Society of Microbiology, Infectious Disease Society of America (Fellow), American Society for the Study of Liver Diseases, Central Society for Clinical Research, HIV Medicine Association, American Academy of HIV Medicine, Association of American Physicians

**Honors and Awards**

- 1974 ----b(6)-----, Drake University
- 1980 -----b(6)-----
- 1980 Mahlon Delp Award (Senior Medical Student Award  
Department of Internal Medicine, Kansas University)
- 1984 Individual National Research Service Award  
(1 F32 AI06988-01) National Institutes of Health
- 1988 Research Associate Award, Veterans Administration
- 1989 Midwest AFCR-Upjohn Award for Excellence in  
Research in Infectious Diseases
- 1991, '96, '09 Nominee, M4 Teacher of the Year
- 1992 Central Society of Clinical Research
- 1994 Fellow, Infectious Diseases Society of America
- 1996 Fellow, American College of Physicians
- 1998-2003 Infectious Diseases Research Advisory Committee, VA (Chair, 2000-2003)
- 1999 Advanced Career Development Award, Veterans Administration
- 1999-present Director, Helen C. Levitt Center for Viral Pathogenesis
- 2002-2007 Virology-Immunology Advisory Committee, Community Program for  
Clinical Research on AIDS.
- 2003-present Hepatitis Working Group. Multicenter AIDS Cohort Study.
- 2003-2006 Safety Monitoring Committee (Chair): NIH-DMID Anthrax vaccine studies
- 2005 NIH Review Panel, Hepatitis C Center Grants
- 2005 Review Panel, Middleton Award, Dept. of Veterans Affairs
- 2005 NIH AIDS and Opportunistic Infection Complications Study Section -Ad hoc
- 2006 VA Career Development Study Section
- 2006-present Association of American Physicians
- 2006-present Editorial Advisory Board, *Journal of Infectious Diseases*
- 2006 ----b(6)-----
- 2006-2010 FDA Vaccines and Related Biological Products Advisory Committee
- 2007-present "America's Top Physicians", Consumers' Research Council of America
- 2007-present Editorial Board, *Retrovirology: Research and Treatment*
- 2007 NIH Virology B Study Section (Temporary Member)
- 2010 Chair, FDA Vaccines and Related Biological Products Advisory Committee

**Areas of Research Interest**

- 1.) GB Virus type replication – epidemiology – HIV interactions
- 2.) Hepatitis C virus attachment, epidemiology, - HIV interactions
- 3.) Antiviral therapy, vaccine and OI clinical trials.

**Current Projects**

- 1. Hepatitis C virus and GB Virus C cell attachment and entry
- 2. Flavivirus interactions with HIV: *in vitro* and *in vivo*.
- 3. Longitudinal study of HCV and GBV-C in HIV cohorts (ACTG, PACTG, MACS, WIHS, WITS, ALIVE, HPTN, and VACS).
- 4. Several Antiviral (HIV, HCV) and Vaccine (HSV, HPV, Pneumovax) clinical trials

**Review Activity: Active Advisory Boards - Consultation:** Food and Drug Administration Vaccines and Related Biological Products Advisory Committee; Journal of Infectious Diseases Editorial Advisory Board; Retrovirology: Research and Treatment Editorial Advisory Board; Multicenter AIDS Cohort Study (MACS): Hepatitis Working Group; NIAID, DMID Safety Monitoring Committee Chair (for 2 recombinant anthrax vaccine studies); External consultant for ----b(6)----- . Liver Action Plan (HIV-HCV co-infection - primary reviewer, NIDDK).

### **Recent Ad Hoc Grants and Contracts Review Activity**

VA Merit Review; UIHC Clinical Research Center; Ontario HIV Network; Health Research Board's Research Project Grants, 2004. Wellcome Trust, 2004, 2005. Site visitor for Laboratory of mycobacterial diseases and cellular immunology, FDA, May, 2007. Chair, site visitor for Laboratory of Virus Diseases, FDA/CBER, April, 2008.

### **Recent Study Section Grant Review Activity**

NHBLI Special Emphasis Grant Review Committee HCV Center Grants, 2000, VA AIDS Centers Review Committee (Chair). VA Infectious Diseases Career Development Award Study Section (chair 2000-2003). NIH Special Emphasis Review Panel on Hepatitis C Virus Cooperative Center Grants, 2005. VA Middleton Award review committee, 2005, VA Career Development Study Section (2006). NIAID Study Section "Virology B" June, 2007.

### **Recent Ad Hoc Reviewer - Journals**

Journal of Virology; Virology; Annals of Internal Medicine; Hepatology; Journal of the American Medical Association; Journal of Medical Virology; American Journal of Medicine; Journal of Infectious Diseases; Journal of Acquired Immune Deficiency Syndromes; Journal of Immunology; Clinical Infectious Diseases; Vaccine; Journal of Clinical Microbiology; Gastroenterology; Archives of Internal Medicine; American Journal of Gastroenterology; Antiviral Therapy; FEBS Letters; AIDS; BioMed Central; Gut Online; European Journal of Clinical Investigation; American Journal of Clinical Nutrition, FEBS Journal; Proceedings of the National Academy of Sciences; Journal of General Virology; PLoS Pathogens; Virus Research; Cell Host and Microbe, American Journal of Tropical Medicine; Int J Cancer, Trans RSocTropMedHyg; J Infect; Blood; PLoS One.

### **Invited Presentations (last 5 years)**

1. GB virus type C: A major factor in HIV long term survival? Visiting Professor, University of Colorado. January 5, 2004.
2. GB virus C infection and Vertical HIV transmission. Women's Interagency Health Study. Bethesda, MD. January 27, 2004.
3. GB virus C: An update. Visiting Professor, St. Louis Univ., Feb 11, 2004.
4. GB Virus C and HIV interactions. Visiting Professor, University of Washington Division of Infectious Diseases. April 19, 2004.
5. Flavivirus models of pathogenesis. Seminar lecutrere, University of Washington Department of Microbiology. April 19, 2004.
6. GB Virus C – HIV Interactions. Rush Medical School Grand Rounds. April 13, 2004.
7. GBV-C inhibits HIV replication. University of Chicago Infectious Diseases Grand Rounds. April 13, 2004.
8. Hepatitis G/GB virus and HIV. Annual HIV/AIDS CME course. Nebraska University, Omaha, NE. October 20, 2004.
9. The effect of GB virus C on HIV replication and disease progression. 2004 Intl Meeting of the Institute of Human Virology. Baltimore, Nov 3, 2004.
10. GB Virus C and the MACS / WIHS Cohorts. 2004 Semiannual Joint Meeting of the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study sponsored by NIAID. November 9, 2004.
11. Mechanistic Studies on GB Virus C inhibition of HIV replication. GB Virus Symposium, Roche Laboratories, Boston, MA. Feb. 21, 2005.
12. Hepatitis G virus, HIV interactions. 21<sup>st</sup> Annual Clinical Virology Symposium. Clearwater Florida. May 9, 2005
13. GB Virus C and HIV Interactions: Molecular explanations for epidemiologic observations. University of North Carolina HIV Conference. May 13, 2005.
14. GB Virus C and HIV. Federal Univ. Rio du Norte, Natal, Brazil, 7/28/05.

### **Invited Presentations (last 5 years – continued)**

15. HIV – GB Virus C Interactions. Departments of Laboratory Medicine, University of Minnesota Grand Rounds. September 27, 2005.
16. GB Virus C and HIV Interactions: Molecular explanations for epidemiologic observations. National Institutes of Health, November 14, 2005.
17. GB Virus C – HIV Interactions: Molecular Insights into epidemiological observations. Institute for Clinical and Molecular Virology. Erlangen, Germany, January 25, 2006.
18. GB Virus C infection slows HIV Disease: Molecular explanations for Epidemiological Observations. Mt. Sinai School of Medicine ID conference. Planned March 1, 2006
19. GB Virus C slows HIV disease progression: Do GBV-C E2 antibodies and their HIV neutralizing effect play a role? Bronx VA Medical Center GI-ID conference. March 2, 2006.
20. Moderator, session on “Infectious Diseases and Addictions: Complicated Therapies for Complicated Diseases” NIDA Satellite Symposium on Clinical approaches to HIV and hepatitis C infections in drug abuse. 37<sup>th</sup> Annual Meeting, American Society of Addiction Medicine. San Diego, May 5, 2006.
21. Drug Interactions in HIV/HCV Co-infected Drug Abusers. NIDA Satellite Symposium on Clinical approaches to HIV and hepatitis C infections in drug abuse. 37<sup>th</sup> Annual Meeting, American Society of Addiction Medicine. San Diego, May 5, 2006.
22. Vaccine Update. Nebraska ID Society. Omaha, NE. September 14, 2006.
23. HIV-Flavivirus Co-infection: HCV is bad, HGV is good. Internal Medicine Grand Rounds, the University of Nebraska. September 15, 2006.
24. Drug interactions among medications used in the treatment of drug addiction and hepatitis C infection. NIH Workshop: American Association for the Study of Liver Disease 57th Annual Meeting. October 29, 2006, Boston, MA.
25. World AIDS Day, Iowa City Program, Nov. 30, 2006.
26. Flavivirus interactions with HIV replication, the role of the NS5 phosphoprotein. Visiting Professor, Case University Department of Molecular Microbiology. March 22, 2007.
27. HIV-Flavivirus Interactions. Visiting Professor, Harvard University Center for AIDS Research, June, 2007.
28. Summary and Co-Chair, poster symposium on Microbial Interactions in HIV-infected cells. XVI International AIDS Society Meeting. Sydney, Australia. July, 2007.
29. Microbial Interaction in infected cells: GBV-C and HIV as a model system. Visiting Professor, Stanford University Dept. of Pathology Grand Rounds. Sept. 26, 2007.
30. Co-Chair, War and Peace Between Microbes: Co-Pathogens as Determinants of HIV. Symposium. XVII International AIDS Society Meeting. Mexico City, Mexico. August 4, 2008.
31. Mechanisms of GBV-C interference with HIV replication in vivo and in vitro. XVII International AIDS Society Meeting. Mexico City, Mexico. August 4, 2008.
32. Co-pathogenic factors influencing HIV disease progression. Royal Infectious Disease Unit, University of Edinburgh. August 29, 2008.
33. How a nonpathogenic virus influences HIV Disease Progression: GBV-C interactions with T cells. National Institute of Childhood Diseases, November 19, 2009.

### University of Iowa Active Committees

1989-2005	University P3 Facility Committee, UI College of Medicine (Chair 93-95)
2005-2007	Internal Medicine VA-University Interactions Committee (Chair)
2007	Search Committee for Infectious Diseases Clinician-Educator Faculty
2007	Search Committee for Infectious Diseases Tenure Track Faculty
2007	Search Committee, Director, University Hygienic Laboratory

### Current Financial Resources

NIH R01: GBV-C HIV Interactions (PI JTS)	2003-2014
VA Merit Review: Characterization of cell GBV-C envelope glycoprotein interactions (PI JTS)	1987-2013
NIH T32: Infectious Diseases Training Grant (PI-JTS)	2004-2010
Ryan White Title IIIb: HIV Service Delivery in Rural Iowa (PI-JTS)	1998-2012
Ryan White Title II: Case Management (PI-JTS)	2003-2011
NIH/DMID: (PI - Apicella) Center for the study of Bacterial Respiratory Pathogens. Stapleton is Co-Principal Investigator (with Winokur) on the clinical component	2003 – 2010
NIH/DMID: (PI – Winokur) Vaccine Treatment and Evaluation Unit Stapleton is head of virology component.	2007-2014
NIH/DMID Subcontract for Herpevac Vaccine (site PI - JTS)	
Merck: HPV Vaccine trials (Future II, V503) (site PI- JTS)	
GSK: HPV Vaccine trials (--b(6)-----) (site PI - JTS)	
Bavarian-Nordic smallpox vaccine trials (PI – JTS)	
NIAID/DMID: Pneumococcal Vaccine Reference Sera	

### Personnel/Trainees

#### **Current Clinical Personnel:**

---b(6)-----	Nurse Practitioner	1988
---b(6)-----	Nurse Practitioner (20%)	1998
---b(6)-----	Social Worker	1998
---b(6)-----	Clinic Nurse	2000
---b(6)-----	Study Coordinator	2005
---b(6)-----	Program Assistant	2007

#### **Current Laboratory Personnel:**

---b(6)-----	Research Technician III	1991
---b(6)-----	Assoc. Research Scientist	1996
---b(6)-----	Research Asst. II	2000
---b(6)-----	Assoc. Research Scientist	2002
---b(6)-----	Senior Research Technician,	2003
---b(6)-----	Med Student (Res. Distinction)	2006
---b(6)-----	MSTP doctoral student	2007
---b(6)-----	USRP	2009

## **BIBLIOGRAPHY**

1. **Stapleton JT**, Gillman MW. Hypoglycemic coma due to norpace toxicity. *S Med J* 76:1453, 1983.
2. **Stapleton JT**, Stamm LV, Bassford PJ. The potential for development of antibiotic resistance in pathogenic treponemes. *Rev Infect Dis* 7:S314-317, 1985.
3. **Stapleton JT**, Jansen R, Lemon SM. Serum neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. *Gastroenterology* 88:1427-1432, 1985.
4. **Stapleton JT**, Lemon SM. Transmission of hepatitis B while monitoring blood glucose. (Letter) *JAMA*, 253:3250, 1985.
5. **Stapleton JT**, Lemon SM. Delta hepatitis, a recently recognized entity. *Diagnosis* 7:26-35, 1985.
6. **Stapleton JT**, Lemon SM. Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus. *J Virol* 61:491-498, 1987.
7. **Stapleton JT**, Lemon SM. New insights into hepatitis A vaccine development. *Infect Med* 4:330-337, 1987.
8. Schwalbe RS, **Stapleton JT**, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. *N Engl J Med* 316:927-931, 1987.
9. Schwalbe RS, **Stapleton JT**, Gilligan PH. Vancomycin resistance in coagulase-negative staphylococcus. *N Engl J Med* 317:766-767, 1987. (letter)
10. **Stapleton JT**, Britz J, Carlson JR, Folds J. A patient with AIDS and a false negative HIV Western blot. *Infect Control* 8:490-491, 1987.
11. **Stapleton JT**, Lange DK. Trypsin sensitivity of epitopes within the Hepatitis A virus immunodominant neutralization site. In: *Vaccines 88*, Ginsberg H, Brown F, Lerner RA, Chanock R (eds), Cold Spring Harbor Press, New York, 1988, pp. 235-240, 1988.
12. Ping LH, Jansen RW, **Stapleton JT**, Murphy PC, Cohen JI, Lemon SM. An immunodominant neutralization site residing on capsid protein VP3 of human hepatitis A virus. *UCLA Symp Mol Cell Biol N Sec* 84:527-537, 1988.
13. Lemon SM, **Stapleton JT**, LeDuc JW, Taylor D, Marchwicki R, Binn LN: A cell culture-adapted variant of hepatitis A virus selected for resistance to neutralizing monoclonal antibody retains virulence in owl monkeys. In: Viral Hepatitis, Zuckerman AJ, ed. Alan R. Liss, New York, 1988, pp. 70-74.
14. Stamm LV, **Stapleton JT**, Bassford PJ. *In vitro* assay to demonstrate high-level erythromycin resistance of a clinical isolate of *treponema pallidum*. *Antimicrob Agents Chemother* 32:164-169, 1988.
15. Mertz GJ, Jones CC, Mills J, Fife K, Lemon SM, **Stapleton JT**, Davis LG, Hill J, and the Acyclovir Study Group: Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection: a multicenter double-blind trial. *JAMA* 260:201-206, 1988.
16. Shamsuddin H, **Stapleton JT**. HIV Infection: Clinical manifestations, therapy and transmission. *Iowa Medicine* 78:125-128, 1988.
17. Kaplan AH, Poza-Juncal E, Shepiro R, **Stapleton JT**. Cure of mucormycosis in a renal transplant recipient receiving maintenance ciclosporin with maintenance of immunosuppression. *Am J Nephrol* 8:139-142, 1988.
18. Ping LH, Jansen RW, **Stapleton JT**, Cohen JI, Lemon SM. Identification of an immunodominant antigenic site involving capsid protein VP3 of hepatitis A virus. *Proc Natl Acad Sci USA* 85:8281-8285, 1988.

19. **Stapleton JT**, Lemon SM. Hepatitis A. In: Infectious Diseases, A Modern Treatise of Infectious Process, P.D. Hoepflich and M.C. Jordan (Eds.), 4th Edition, J.B. Lippincott Company, Philadelphia, Chapter 78, pp. 758-766, 1989.
20. Balfour HH, Chase BN, **Stapleton JT**, Simmons RL, Fryd DS. Acyclovir prevents cytomegalovirus disease in renal allograft recipients. *N Eng J Med* 320:1381-1387, 1989.
21. **Stapleton JT**. HIV transmission, health care workers, and media hype. (Editorial). *Infect Control Hosp Epidemiol* 10:503-504, 1989.
22. Lemon SM, Binn LN, Marchwicki R, Murphy P, Ping L, Jansen RW, Asher LVS, **Stapleton JT**, Taylor D, LeDuc JW. *In vivo* replication and reversion to wild type of a neutralization-resistant antigenic variant of hepatitis A virus. *J Infect Dis* 161:7-13, 1990.
23. Veach L, **Stapleton JT**. Mechanical ventilation for pneumocystis carinii pneumonia in AIDS. *Chest* 97:1499-1500, 1990.
24. Cox E, Emerson S, Lemon S, Ping L, **Stapleton J**, Guiler M, Feinstone S. Use of oligonucleotide directed mutagenesis to define the immunodominant neutralization antigenic site of hepatitis A virus. In: Vaccines 90, H. Ginsberg, F. Brown, R.A. Lerner, and R. Chanock (Eds.), Cold Spring Harbor Press, p. 169-173, 1990.
25. **Stapleton JT**, Lange DK, LeDuc JW, Binn LN, Jansen R, Lemon SM: The role of secretory immunity in Hepatitis A virus infection. *J Infect Dis* 163:7-11, 1991.
26. Hughes D, **Stapleton JT**. Postoperative toxic shock syndrome. *Iowa Medicine* 81:55-58, 1991.
27. **Stapleton JT**, Rosen E, McLinden J. Detection of hepatitis A virus capsid proteins in insect cells infected with recombinant baculoviruses encoding the entire HAV open reading frame. In: Viral Hepatitis and Liver Disease, Hollinger, F.B. ed. Williams & Wilkins, p. 50-54, 1991.
28. Day S, Lemon S, Sharpe D, **Stapleton JT**, Cox E, Feinstone S, Stein L. Evaluation of the human B lymphocyte response to hepatitis A virus (HAV). In: Viral Hepatitis and Liver Disease, Hollinger, F.B. ed. Williams & Wilkins, p. 69-70, 1991.
29. Ferguson KJ, **Stapleton JT**, Helms CM. Physicians' effectiveness in assessing risk for HIV infection. *Arch Intern Med* 151:561-564, 1991.
30. McLinden J, Rosen E, **Stapleton JT**. Anti-HAV neutralizing antibodies made to antigens produced by recombinant baculoviruses. In: Vaccines 91: Modern Approaches to New Vaccines, Cold Spring Harbor Press, p. 239-244, 1991.
31. Densen P, **Stapleton JT**. Is the AIDS epidemic ending? *Iowa Medicine* 81:167-169, 1991.
32. **Stapleton JT**. Book Review of Textbook of Human Virology, Robert B. Belshe (ed.). *Infect Control Hosp Epidemiol* 12:391-392. 1991.
33. Winokur PL, McLinden J, **Stapleton JT**. The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into virus-like particles. *J Virol* 65:5029-5036, 1991.
34. Davis KA, **Stapleton JT**. Migration to rural areas by HIV patients: Impact on HIV related health care delivery. *Infect Control Hosp Epidemiol* 12:540-544, 1991.
35. **Stapleton JT**, Frederick J, Meyer B. Hepatitis A virus attachment to cultured cell lines. *J Infect Dis* 164:1098-1103, 1991.
36. **Stapleton JT**. Viral Hepatitis. *Medical and Health Annual*. Encyclopaedia Britannica, Inc., p.342-347, 1992.
37. Winokur PL, **Stapleton JT**. Immunoglobulin prophylaxis of Hepatitis A virus. *Clin Infect Dis* 14:580-586, 1992.





57. **Stapleton JT**, Lemon SM. New vaccines against hepatitis A. In: New Generation Vaccines, M.R. Levine, G.C.Woodrow, J.B. Kaper, G.S.Cobon, eds. Second Edition, Marcel Dekker, Inc. New York, pp 571-585, 1997.
58. Han J-Q, **Stapleton JT**. Hepatitis A through G. Medical and Health Annual. Encyclopaedia Britannica, Inc., Bernstein E, ed., pp 235-239, 1997.
59. Schmidt WN, Wu P, Han, JQ, Perino MJ, LaBrecque DR, **Stapleton JT**. Distribution of Hepatitis C Virus (HCV) RNA in whole blood and blood cell fractions: Plasma HCV RNA analysis underestimates circulating viral load. *J Infect Dis.* 176:20-27, 1997.
60. Schmidt WN, Wu P, Cederna J, Mitros FA, LaBrecque DL, **Stapleton JT**. Surreptitious Hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. *J Infect Dis.* 176:27-33, 1997.
61. Han J-Q, **Stapleton JT**. Assay of amino acid mutagenesis in hepatitis A virus cellular receptor binding region. *Virologica Sinica* 12:239-243, 1997.
62. Han J-Q, Schmidt WN, Wu P, Loh P-M, Neil G, LaBrecque DR, **Stapleton JT**. Specific binding of hepatitis C virus to the Fc fragment of IgG molecules. *Virologica Sinica* 12:244-247, 1997.
63. Cook,RT, **Stapleton JT**, Fein G, Shearer GM. Symposium: Alcohol and Human Immunodeficiency Virus Infection. *Alcoholism Clin Exp Res.* 20(supplement 8):210A-215A. 1997.
64. Li F, Cook RT, Rasmussen W, **Stapleton JT**, Ballas Zk. Ethanol and natural killer cells. II. Stimulation of human natural killer activity by ethanol in vitro. *Alcoholism Clin Exp Res.* 21:981-987, 1997.
65. Cook R, **Stapleton JT**, Ballas Z, Klinzman D. Effects of a single ethanol exposure on HIV replication in human lymphocytes. *J Investig Med.* 45:265-271, 1997.
66. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA, and the AIDS Clinical Trials Group 320 Study Team (including **Stapleton JT**) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. *N Engl J Med.* 337:725-733. 1997
67. Wünschmann S, Vallbracht A, Flehmig B, Winokur P, Klinzman D, **Stapleton JT**. Cytolytic T lymphocyte epitopes are present on hepatitis A virus structural proteins. In: *Viral Hepatitis and Liver Disease*, eds. Rizzetto M, Purcell RH, Gerin JL, and Verme G. Edizioni Minerva Medica. Turin. pp. 51-54, 1997.
68. Han J-Q, Schmit WN, Wu P, Loh P, Neil G, LaBrecque DR, **Stapleton JT**. Specific binding of hepatitis C virus to the Fc fragment of immunoglobulin molecules. In: *Viral Hepatitis and Liver Disease*, eds. Rizzetto M, Purcell RH, Gerin JL, and Verme G. Edizioni Minerva Medica. Turin. pp. 228-231, 1997.
69. Lemon SM, **Stapleton JT**. Hepatitis A Virus: Prevention. In: Viral Hepatitis, Zuckerman AJ, Thomas HC, eds. 2<sup>nd</sup> Edition, Churchill Livingstone, Edinburgh, p. 63-76, 1998.
70. Fineberg JE, Hurwitz Sh, Cooper D, Sattler FR, MacGregor RR, Powderly W, Holland GN, Griffiths PD, Pollard RB, Youle M, Gill MJ, Holland FJ, Power ME, Owens S, Coakley D, Fry J, Jacobson MA, and the AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group (including **Stapleton JT**). A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. *J. Infect. Dis.* 177:48-56, 1998.

71. LaBrecque FD, LaBrecque DR, Klinzman D, Perlman S, Cederna JB, Winokur PL, Han J-Q, **Stapleton JT**. Recombinant Hepatitis A Virus Antigen: Improved Production and Utility in Diagnostic Immunoassays. *J Clin Microbiol.* 36:2014-2018, 1998.
72. **Stapleton JT**, Han J-Q, Schmidt WN, and LaBrecque DR. Hepatitis C Virus Fc Binding Domain. United States Patent No. 5,846,735, 1998.
73. Shutt DC, Jenkins LM, Carolan EJ, **Stapleton J**, Daniels KJ, Kennedy RC, Soll DR. T cell syncytia induced by HIV release T cell chemoattractants: demonstration with a newly developed single cell chemotaxis chamber. *J Cell Sci.*, 111:99-109, 1998.
74. Xiang, JH, Klinzman D, McLinden J, Schmidt WN, LaBrecque DR, Gish R, **Stapleton JT**. Characterization of Hepatitis G Virus (GB-C Virus) Particles: Evidence for a Nucleocapsid and Expression of Sequences Upstream of the E1 Protein. *J Virol.* 72:2738-2744, 1998.
75. Schmidt WN, Wu P, Brashear D, Klinzman D, Perino-Phillips MJ, LaBrecque DR, **Stapleton JT**. Effect of Interferon therapy on hepatitis C virus in RNA Whole Blood, Plasma and Peripheral Blood Mononuclear Cells. *Hepatology* 28:1110-1116, 1998.
76. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JPA, Holohan MK, Leavitt R, Goone G, Richman DD and the AIDS Clinical Trials Group Study 343 Team (including **Stapleton JT**). Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. *N Engl J Med* 339:1261-8, 1998.
77. Noormohamed SE, Katseres JK, **Stapleton JT**. Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals. *Renal Failure* 20: 20:627-633, 1998.
78. Xiang J, Daniels KJ, Soll DR, Schmidt WN, LaBrecque DR, **Stapleton JT**. Visualization and Characterization of GB Virus – C Particles: Evidence for a Nucleocapsid. *J. Viral Hep.* 6:S16-22, 1999.
79. **Stapleton JT**. Hepatitis A: Biology, Pathogenesis, Epidemiology, Clinical Description, and Diagnosis. In: Viral Hepatitis: Diagnosis, Therapy and Prevention. Steven Spector, ed., Humana Press, Totowa, NJ. pp.7-33, 1999.
80. Xiang, JH, **Stapleton JT**. Hepatitis A. *Manual of Clinical Microbiology*, Murray PR, Baron EJ, Pfaller MA, Tenover FC, Tenover FC, eds., 7th ed., ASM Press, Washington, DC, pp.1014-1024, 1999.
81. George S, **Stapleton JT**. Status of Viral Hepatitis Vaccines. *Clinical Microbiology Newsletter.* *Clinical Microbiology Newsletter* 21:113-118, 1999.
82. Herman RA, Noormohamed S, Hirankarn S, Shelton, Huang E, Gene D. Morse GD, Hewitt RG, **Stapleton JT**. Comparison of a Neural Network Approach with Five Traditional Methods for Creatinine Clearance Prediction in Patients with Human Immunodeficiency Virus Infection. *Pharmacotherapy*, 19:734-740, 1999.
83. El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour HH, Eng R, Hooton TM, Kerkering TM, Schutz M, van der Horst C, Hafner R and the Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group (including **Stapleton JT**). Atovaquone compared with dapsone for the prevention of *Pneumocystis carinii* pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. *N Engl J Med.* 339:1889-1895, 1999.
84. George SL, Swindells S, Knudson R, **Stapleton JT**. Unexplained Thrombosis in HIV Infected Patients Receiving Protease Inhibitors: Report of Seven Cases. *Am. J. Med.* 107:624-630, 1999

85. **Stapleton JT**, Klinzman D, Schmidt WN, Pfaller MA, Wu P, LaBrecque DR, Han J-Q, Perino-Phillips MJ, Woolson R, Alden B. Prospective Comparison of Whole Blood- and Plasma-Based Hepatitis C Virus RNA Detection Systems: Improved Detection Using Whole Blood as the Source of Viral RNA. *J. Clin. Micro.* 37:484-489, 1999.
86. Cederna, JB, Klinzman D, **Stapleton, JT**. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. *Vaccine*, 18:892-898, 2000.
87. Schmidt WN, **Stapleton JT**, LaBrecque DR, Mitros FA, Kirby PA, Phillips MJ, Brashear DL. Hepatitis C virus (HCV) infection and cryoglobulinemia: Analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology. *Hepatology* 31:737-744, 2000.
88. Wünschmann S and **Stapleton JT**. Fluorescence-based quantitative methods for detecting Human Immunodeficiency Virus Type 1-induced syncytia. *J Clin Micro.* 38:3055-3060, 2000.
89. Xiang J, Wünschmann S, Schmidt WN, Shao J, **Stapleton JT**. Full-length GB virus C (Hepatitis G Virus) RNA transcripts are infectious in primary CD4 positive T cells. *J. Virol.* 74:9125-9133, 2000.
90. Wünschmann S, Medh J, Klinzman D, Schmidt WN, **Stapleton JT**. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low density lipoprotein receptor. *J. Virol.* 74:10055-10062, 2000.
91. Vargas K, Messer SA, Pfaller M, Lockhart S, **Stapleton JT**, Hellstein J, Soll DR. Elevated switching and drug resistance of *Candida* from HIV-Positive individuals prior to thrush. *J. Clin. Micro.* 38:3595-3607, 2000.
92. Xiang J, Wünschmann S, Diekema D, Klinzman DJ, Patrick KD, George SL, **Stapleton JT**. Effect of CoInfection with GB Virus C on Survival Among Patients with HIV Infection. *N.Engl.J.Med.* 345:707-714, 2001.
93. Schmidt WN, **Stapleton JT**. Whole-Blood Hepatitis C Virus RNA Extraction Methods (letter). *J. Clin. Micro.* 39:3812, 2001.
94. **Stapleton JT**. GB Virus C Delays Mortality in HIV-Infected Individuals. *Biomedicine & Pharmacotherapy.* 56:111-113. 2002.
95. George S, Klinzman D, Schmidt WN, Patrick K, Alden B, Pfaller MA, **Stapleton JT**. Antibody negative HCV infection in HIV positive individuals. In: Viral Hepatitis and Liver Disease. Margolis HS, Alter MJ, Liang TJ, Dienstag JL eds., International Medical Press. London, p 357-361, 2002.
96. Xiang J, Wünschmann S, Schmidt WN, Shao J, **Stapleton JT**. In vitro replication of a GB Virus C infectious clone. In: Viral Hepatitis and Liver Disease. Margolis HS, Alter MJ, Liang TJ, Dienstag JL eds., International Medical Press. London, p 464-468, 2002.
97. **Stapleton JT**, Diekema DJ, Xiang J. GB virus C and mortality from HIV infection. (letter) *N.Engl.J.Med.* 346:378. 2002.
98. **Stapleton JT**, Xiang J, George S, Klinzman D. Evidence for delayed human immunodeficiency virus (HIV) disease progression in HIV-GB virus C co-infected individuals. In: Viral Hepatitis and Liver Disease. Margolis HS, Alter MJ, Liang TJ, Dienstag JL eds., International Medical Press. London, p 469-472, 2002.
99. Ullrich PM, Lutgendorf SK, **Stapleton, J**. Social constraints and depression in HIV infection: Effects of sexual orientation and area of residence. *Journal of Social and Clinical Psychology* 211:47-66. 2002.

100. Kresina TF, Flexner CW, Sinclair J, Correia MA, **Stapleton JT**, Adeniyi-Jones S, Cargill V, Cheever LW. Alcohol Use and HIV Pharmacotherapy. *AIDS Res. Hum. Retro.* 18:757-770, 2002.
101. Xiang J, Wünschmann S, Schmidt WN, George S, Schmidt WN, LaBrecque DR, **Stapleton JT**. Recombinant hepatitis C virus-like particles expressed by baculovirus: Utility in cell-binding and antibody detection assays. *J.Med.Virol.* 68:537-543, 2002.
102. George SL, Gephardt J, Klinzman D, Foster MB, Patrick KD, Schmidt WN, Alden B, Pfaller MA, **Stapleton JT**. Hepatitis C virus (HCV) viremia in HIV-infected individuals with negative HCV antibody tests. *J. Acquir. Immune Defic. Syndr.* 31:154-162, 2002.
103. George SL, Wünschmann S, McCoy J, Xiang J, **Stapleton JT**. Interactions between GB Virus type C (also known as hepatitis G virus) and HIV. *Current Infectious Disease Reports* 4:550-558, 2002.
104. Brown EA and **Stapleton JT**. Hepatitis A. *Manual of Clinical Microbiology*, Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover BC, eds., 8th ed., ASM Press, Washington, DC, p. 1452-1463, 2003.
105. Ullrich PM, Lutgendorf SK, **Stapleton JT**. Concealment of homosexual identity, social support and CD4 cell count among HIV-seropositive gay men. *J Psychosomatic Res.* 54:205-212, 2003.
106. Valdez H, Mitsuyasu R, Landay A, Sevin AD, Chan ES, Srtizler J, Kalams SA, Pollard RB, Fahey J, Fox L, Namkung A, Estep S, Moss R, Sahner D, Lederman MM. Interleukin-2 increases CD4+ lymphocyte numbers but does not enhance responses to immunization: Results of A5046s. *J Infect Dis* 187:320-325, 2003. (**Stapleton JT** acknowledged for UI contribution).
107. **Stapleton JT**. Hepatic and Pancreatic Diseases in HIV Infection. In: Approach Towards Management of Human Immunodeficiency Virus Infection and Its Related Complications. Singh N, Shafer RW, and Swindells S, eds., ESUN Technologies, Pittsburgh. Online Text at: [www.antimicrobe.org](http://www.antimicrobe.org). 2003. Condensed chapter in *HIV Clinical Manual*, pp. 181 – 213, 2003.
108. **Stapleton JT**. GB Virus type C/Hepatitis G Virus. *Seminars in Liver Disease.* 23:137-148. 2003.
109. Polgreen PM, Putz D, **Stapleton JT**. Inaccurate glycosylated hemoglobin A1C measurements in HIV-positive patients with diabetes mellitus. *Clin Infect. Dis.* 37:e53-56, 2003.
110. Polgreen P, Xiang J, **Stapleton JT**. GB Virus C – HIV Co-Infection. *Microbes and Infection.* 5:1255-1261, 2003.
111. George S, Xiang J, **Stapleton JT**. Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. *Virology.* 316:191-201, 2003.
112. Williams CF, Klinzman D, Yamashita T, Xiang J, Polgreen PM, Rinaldo C, Liu C, Phair J, Margolick JB, Zdunek D, Hess G, **Stapleton JT**. Persistent GB virus C infection and survival in HIV-infected men. *N.Engl.J.Med.*, 350:981-990, 2004.
113. Kim SJ, Jang MH, **Stapleton JT**, Yoon SO, Jeon ES, and Hong HJ. Neutralizing Human Monoclonal Antibodies to Hepatitis A Virus Recovered by Phage Display. *Virology.* 318:598-607, 2004.
114. **Stapleton JT**, Williams CF, Xiang J. GB Virus C: A beneficial infection? *J.Clin.Micro.* 42:3915-3919, 2004.

115. Klinzman D, Katz L, George SL, Chang Q, Xiang J, Zdunek D, Hess G, Schmidt WN, LaBrecque DR, **Stapleton JT**. GB virus C/hepatitis G virus: Does clearance of viremia differ based on mode of transmission? In: 11<sup>th</sup>:International Symposium on Viral Hepatitis and Liver Disease, p 488-90. Jilbert AR, Grgacic EVL, Vickery K, Burrl CJ, Cossart EE, eds. Australian Center for Hepatitis Virology, publisher. Melbourne, 2004.
116. Xiang J, George SL, Wünschmann S, Chang Q, Klinzman D, **Stapleton JT**. . GB virus C/hepatitis G virus: In vivo and in vitro beneficial interactions with HIV. In: 11<sup>th</sup>:International Symposium on Viral Hepatitis and Liver Disease, p 494-496. Jilbert AR, Grgacic EVL, Vickery K, Burrl CJ, Cossart EE, eds. Australian Center for Hepatitis Virology, publisher. Melbourne, 2004.
117. Polgreen PM, Fultz SL, Justice AC, Wagner JH, Diekema DJ, Rabeneck L, Weissman S, **Stapleton JT**. Association of Hypocholesterolemia With Hepatitis C Virus Infection in HIV Infected People. *HIV Med.* 5:144-150, 2004.
118. Ullrich PM, Lutgendorf SK, **Stapleton JT**, Horowitz M. Self Regard and Concealment of Homosexuality as Predictors of CD4+ Cell Count Over Time Among HIV Seropositive Gay Men. *Psychology & Health.* 19:183-196, 2004.
119. Xiang J, George SL, Wünschmann S, Chang Q, Klinzman D, **Stapleton JT**. GB virus C infection inhibits HIV-1 replication by increasing RANTES, MIP-1 $\alpha$ , MIP-1 $\beta$ , and SDF-1. *Lancet*, 363:2040-2046, 2004.
120. Weintraub A, Hamilton JD, Hahn C, Klinzman D, Moyo G, Zdunek D, Hess G, Benjamin DK, **Stapleton JT**. Active or Prior GB Virus C Infection Does Not Protect Against Vertical Transmission of HIV in Co-Infected Women from Tanzania. *Clin. Infect. Dis.* 38:e46-48, 2004.
121. **Stapleton JT**, Schmidt WN, Katz L. Seronegative hepatitis C virus infection, not just RNA detection. *J Infect Dis.* 190:651-652, 2004.
122. **Stapleton JT**, Williams CF, Xiang J. GB virus C and HIV interactions (letter). *N.Engl.J.Med.*, 350:2618,2004, 2004.
123. **Stapleton JT**, Chaloner K. GB Virus C and survival in HIV-positive people. *AIDS.* 18:2343-2344, 2004.
124. Talbot TR, **Stapleton JT**, Brady RC, Winokur PL, Bernsteing DI, Germanson T, Yoder SM, Rock MT, Crowe JR. JE, Edwards KM. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: A randomized controlled trial. *JAMA* 292:1205-1212, 2004.
125. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C, and AIDS Clinical Trials Group A5071 Study Team (including **Stapleton JT**). Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. *N.Engl.J.Med.*, 351:451-459, 2004.
126. **Stapleton JT**, Xiang J, Wuenschmann S, and Schmidt WN. United States Patent No. 6,870,043 Full-length GB virus C (Hepatitis G Virus) RNA transcripts are infectious in primary CD4 Positive T cells and Methods of treating HIV. 2005.
127. Xiang J, Martinez-Smith C, Gale Jr. M, Chang Q, LaBrecque DR, Schmidt WN, **Stapleton JT**. GB Virus type C NS5A sequence polymorphisms: Association with interferon susceptibility and inhibition of PKR-mediated eIF-2 $\alpha$  phosphorylation. *J Interferon Cytokine Res.* 25:261-270, 2005.

128. Schuval S, Lindsey JC, **Stapleton JT**, Van Dyke RB, Palumbo P, Mofenson LM, Oleske JM, Cervia J, Kovacs A, Dankner WN, Smith E, Nowak B, Ciupak G, Webb N, Eagle M, Smith D, Hennessey R, Goodman-Kerkau M, Klinzman D, Hess G, Zdunek D, Levin MJ; the Pediatric AIDS Clinical Trials Group Protocol 1028S Team. GB Virus C Infection in Children With Perinatal Human Immunodeficiency Virus Infection. *Pediatr Infect Dis J*. 24:417-422, 2005.
129. **Stapleton JT**, Chaloner K, Williams CF. GB virus C and survival in the Amsterdam Cohort Study. *J Infect Dis*. 191:2157-2158. 2005.
130. **Stapleton, JT**. GBV-C Coinfection and prolonged survival in HIV: The questions persist (editorial). *Clinical Care Options: HIV*. Online journal, May 25, 2005.
131. Bisson G, Strom B, Gross R, Weissman D, Klinzman D, Hwang W-T, Kostman J, Hess G, Zdunek D, Metzger D, **Stapleton JT**, Frank I. Effect of GB virus C viremia on HIV acquisition and HIV set-point. *AIDS*. 19:1910-1912, 2005.
132. Xiang J, Sathar MA, McLinden J, Klinzman D, Chang Q, **Stapleton JT**. South African GB virus C isolates: Interactions between genotypes 1 and 5 GBV-C isolates and the human immunodeficiency virus. *J. Infect. Dis*. 192:2147-2151, 2005.
133. Souza IE, Zhang W, Diaz RS, Chaloner K, Klinzman D, **Stapleton JT**. Effect of GB Virus C on response to antiretroviral therapy in HIV infected Brazilians. *HIV Med* 7:25-31, 2006.
134. Zhang W, Chaloner K, Tillmann HL, Williams CF, **Stapleton JT**. Effect of early and late GBV-C viremia on survival of HIV infected individuals: a meta-analysis. *HIV Med*, 7:173-180, 2006.
135. George SL, Varmaz D, **Stapleton JT**. GB virus C replicates in primary T and B lymphocytes. *J. Infect. Dis*. 193:451-454, 2006.
136. Souza IE, Allen JB, Xiang J, Klinzman D, Diaz R, Zhang S, Chaloner K, Zdunek D, Hess G, Williams CF, Benning L, **Stapleton JT**. Optimal testing for GB Virus C viremia: Effect of primer selection on estimates of GBV-C prevalence and response to antiretroviral therapy. *J. Clin. Microbiol*. 44:3105-3113, 2006.
137. **Stapleton JT**, Xiang J, Williams CF. GBV-C and HIV survival (letter). *Lancet Infect. Dis*. 6:187, 2006.
138. Wünschmann S, Müller HM, Stipp CS, Hemler ME, **Stapleton JT**. *In Vitro* interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs. *J. Infect. Dis*. 194:1058-1067, 2006.
139. Xiang J, McLinden JH, Chang Q, Kaufman TM, **Stapleton JT**. An 85 amino acid segment of the GB Virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T-cells. *Proc Natl Acad Sci USA*, 103:15570-15575, 2006.
140. Johannsson, B and **Stapleton JT**. Bacterial and Miscellaneous Infections of the Liver. In: Zakim Boyer Hepatology: A textbook of Liver Disease, Chapter 37, 5<sup>th</sup> ed. Boyer T, Wright T, and Manns M, Eds. 2006.
141. McLinden JH, Kaufman TM, Xiang J, Chang Q, Klinzman D, Engel AM, Hess G, Schmidt U, Houghton M, **Stapleton JT**. Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding. *J Virol*, 80:12131-12140. 2006.
142. Kayali Z, Tan S, Shinkunas L, Voigt M, LaBrecque DR, **Stapleton JT**, Brown KE, Schmidt WN. Risk Factors for Hepatitis C Fibrosis: A Prospective study of United States Veterans compared to Non-veterans. *J Viral Hep*, 14:11-21, 2007.

143. Chamie G, Bonacini M, Bangsberg DR, **Stapleton JT**, Hall C, Overton ET, Scherzer R, Tien PC. Factors associated with seronegative chronic hepatitis C virus infection in HIV-infection. *Clin Infect Dis* 44:577-583, 2007.
144. Couch RB, Winokur P, Edwards KM, Black S, Atmar RL, **Stapleton JT**, Kissner JM, Shinefield H, Denny TM, Michael J. Bybel, Newman FK, Yan L. Reducing the Dose of Smallpox Vaccine Reduces Vaccine-Associated Morbidity Without Reducing Vaccination Success Rates or Immune Responses. *J Infect Dis.* 195:826-832, 2007.
145. Dillon DMB, **Stapleton JT**. Selenium effects on HIV RNA and CD4 Cell Counts. *Arch Intern Med.* 167:1556-1557 2007.
146. Kaufman TM, McLinden JH, Xiang J, Engel AM, **Stapleton JT**. The GBV-C envelope glycoprotein E2 does not interact specifically with CD81. *AIDS* 21:1045-1048, 2007.
147. Future II Study Group (including **Stapleton J**). Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. *N Engl J Med* 356:1915-1927, 2007.
148. **Stapleton JT**, Xiang J, George SL. United States Patent No. 7,291,723 GB virus C and methods of treating viral infections. 2007.
149. Handelsman E, Cheng I, Thompson B, Hershow R, Mofenson LM, Hollinger FB, Chen KT, Burchett SK, Klinzman D, **Stapleton JT** and the Women and Infants Transmission Study Group (WITS). Impact of GB Virus type C Infection on Mother-to-Child HIV Transmission in the Women and Infants Transmission Study Cohort. *HIV Medicine*, 8:561-567. 2007.
150. Scherer CA, Magness CL, Steiger KV, Poitinger ND, Caputo CM, Miner DG, Winokur PL, Klinzman D, McKee J, Pilar C, Ward PA, Gillham MH, Haulman NJ, **Stapleton JT**, Iadonato SP. Distinct Gene Expression Profiles in Peripheral Blood Mononuclear Cells from Patients Infected with Vaccinia Virus, Yellow Fever 17D Virus, or Community Acquired Upper Respiratory Infections. *Vaccine* 25:6458-73, 2007.
151. Chang Q, McLinden JH, **Stapleton JT**, Sathar AM, Xiang J. GB Virus C NS5A protein from genotypes 1, 2, 3, and 5 and a 30 amino acid NS5A fragment expression inhibit HIV-1 replication in a CD4+ T-lymphocytes. *J Gen Virol* 88:3341-3346, 2007.
152. **Stapleton JT**, Bennett K, Bosch RJ, Polgreen PM, Swindells S. Effect of antiretroviral therapy and hepatitis C coinfection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy. *HIV Clin Trials*, 8:429-436, 2007.
153. **Stapleton J**. A new variable influencing HCV-related liver disease in HIV-HCV co-infected individuals? *Gastroenterology*, 133:2042-2045, 2007.
154. Zhang W, Chaloner K, Cowles MK, Zhang Y, **Stapleton JT**. A Bayesian analysis of doubly censored data using a hierarchical Cox model. *Statist. Med.* 27:529-542, 2008.
155. Graziano F, Kettoola S, Munshower J, **Stapleton JT**, Towfic G. Effect of spatial distribution of T-cells and HIV load on HIV progression. *Bioinformatics.* 24:855-860, 2008.
156. Xiang J, McLinden JH, Chang Q, Jordan EL, **Stapleton JT**. Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication, *PLoS One.* 3:e2580 (p. 1-10), 2008.
157. McLinden JH, **Stapleton JT**, Chang Q, Xiang J. Expression of the dengue virus type 2 NS5 protein in a CD4+ T cell line inhibits HIV replication. *J Infect Dis.* 198:860-863, 2008.

158. **Stapleton JT**, Balfour HH, Jr. Coinfection alters the playing field: herpesviruses induce acyclovir to inhibit HIV. *Cell: Host and Microbe*. 4:194-195. 2008.

159. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H, for the MOTIVATE Study Teams (including **Stapleton JT**). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. *N Engl J Med* 359:1429-1441, 2008.

160. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams (Including **Stapleton JT**). Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. *N Engl J Med* 359:1442-1455, 2008

161. Blankson JN, Klinzman D, Astemborski J, Thomas DL, Kirk GD, **Stapleton JT**. Low frequency of GB virus C viremia in a cohort of HIV-1 infected elite suppressors. *AIDS*. 22:2398-2400, 2008.

162. Zhang W, Zhang Y, Chaloner K, **Stapleton JT**. Imputation Methods for Doubly Censored HIV Data. *J. Stat. Comp. Sim.*, 79:1245-1257. 2009.

163. Mohr EJ, **Stapleton JT**. GB virus type C interactions with HIV: The role of envelope glycoproteins. *J Viral Hep*, 16:757-768. 2009.

164. **Stapleton JT**, Chaloner K, Zhang J, Klinzman D, Souza IE, Xiang J, Landay A, Fahey J, Pollard R, Mitsuyasu R. **GB** virus C viremia is associated with reduced CD4 expansion following interleukin 2 therapy in HIV-infected people receiving HAART. *AIDS* 23:605-610, 2009.

165. **Stapleton JT**. Comment on: GBV-C infection: a silent anti-HIV panacea within? *Trans R Soc Trop Med Hyg*. 103:1291-1292, 2009.

166. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Costellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Djenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, for the HPV PATRICIA Study Group (including **Stapleton J**). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. In Press. *Lancet*. 374:301-314, 2009.

167. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Geiseler J, Daar ES, ACTG Study 5202 Team (**Including Stapleton JT**). Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy. *N Engl J Med* 361:2230-2240, 2009.

167. Xiang J, McLinden JH, Rydze RA, Chang Q, Kaufman TM, Klinzman D. **Stapleton JT**. Expression of Non-Structural Protein 5 by Human Flaviviruses Inhibits HIV Replication by Down Regulation of CD4 Expression on T-Lymphocytes. *J Immunol*, 183:7860-9.2009.

168. ----b(4)-----  
-----  
-----

169. -----b(4)-----  
-----



**Other:**

- 1992 Mini-Sabbatical: 3 months hosted by --b(6)-----, M.D., Ph.D., University of Tuebingen. Cell mediated immune responses to recombinant hepatitis A virus particles.
- 1999 Sabbatical: 2 months hosted by --b(6)-----, Ph.D., University of Edinburgh, 10 months with --b(6)---, University of Iowa. Project: HIV coinfection with HCV and or GB Virus C. Funded by VA Career Development award
- 2008 Sabbatical: University of Edinburgh hosted by --b(6)-----, Ph.D.

Inventor on U.S. Patents:

- No. 5,294,548: Recombinant Hepatitis A Virus Vaccine
- No. 5,846,735, 1998: "Hepatitis C Virus Fc Binding Domain"
- No. 6,870,043. "Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4 positive T cells"
- No. 7,291,723 "GB virus C and methods of treating viral infections".